Canada vs Hong Kong, China: Previously treated cases tested for RR-/MDR-TB
Canada
88.0%
in 2024
Hong Kong, China
87.0%
in 2024
Canada rank
90th
Hong Kong, China rank
92nd
Previously treated cases tested for RR-/MDR-TB over time
- Canada
- Hong Kong, China
How they compare
Canada currently reports 88.0% against 87.0% in Hong Kong, China, a difference of 1.0%.
The two have swapped places 2 times across 13 shared years of data; in 2007 it was Canada ahead.
Canada ranks 90th and Hong Kong, China ranks 92nd of 180 countries.
Across the 3 decades both report, Canada averaged higher in 2 and Hong Kong, China in 1.
Head to head by decade
| Decade | Canada | Hong Kong, China | Difference | Ahead |
|---|---|---|---|---|
| 2000s | 75.3% | 53.3% | 22.0% | Canada |
| 2010s | 76.0% | 54.0% | 22.0% | Canada |
| 2020s | 78.8% | 88.0% | 9.2% | Hong Kong, China |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher previously treated cases tested for rr-/mdr-tb, Canada or Hong Kong, China?
- Canada, at 88.0% against 87.0% in Hong Kong, China as of 2024.
- What is the difference in previously treated cases tested for rr-/mdr-tb between Canada and Hong Kong, China?
- 1.0%, with Canada ahead.
- How many years of comparable data are there for Canada and Hong Kong, China?
- 13 years are reported by both, from 2007 to 2024.
- How do Canada and Hong Kong, China rank globally for previously treated cases tested for rr-/mdr-tb?
- Canada ranks 90th and Hong Kong, China ranks 92nd of 180 countries.
- Where does this data come from?
- World Health Organization, Global Health Observatory, published as Previously treated cases tested for RR-/MDR-TB (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.